Skip to main content
PMC home page
Journal of Enzyme Inhibition and Medicinal Chemistry logoLink to Journal of Enzyme Inhibition and Medicinal Chemistry
. 2019 Dec 2;35(1):280–288. doi: 10.1080/14756366.2019.1697249

Plasmatic exosomes from prostate cancer patients show increased carbonic anhydrase IX expression and activity and low pH

Mariantonia Logozzi a,✉, Davide Mizzoni a, Clemente Capasso b, Sonia Del Prete b, Rossella Di Raimo a, Mario Falchi c, Daniela F Angelini d, Alessandro Sciarra e, Martina Maggi e, Claudiu T Supuran f, Stefano Fais a,✉
PMCID: PMC6896418  PMID: 31790614

Abstract

Acidity, hypoxia and increased release of exosomes are severe phenotypes of tumours. The regulation of pH in tumours involves the interaction of several proteins, including the carbonic anhydrases which catalyze the formation of bicarbonate and protons from carbon dioxide and water. Among CA isoforms, CA IX is over-expressed in a large number of solid tumours, conferring to cancer cells a survival advantage in hypoxic and acidic microenvironment, but there isn’t evidence that CA IX expression could have a real clinical impact. Therefore, in this study for the first time the expression and activity of CA IX have been investigated in the plasmatic exosomes obtained from patients with prostate carcinoma (PCa). For this purpose, the study was performed through different methodological approaches, such as NTA, western blot analysis, enzyme activity assay, Nanoscale flow cytometry, ELISA, confocal microscopy. The results showed that PCa exosomes significantly overexpressed CA IX levels and related activity as compared to healthy donors. Furthermore, CA IX expression and activity were correlated to the exosome intraluminal pH, demonstrating for the first time that PCa exosomes are acidic. Our data suggest the possible use of the exosomal CA IX expression and activity as a biomarker of cancer progression in PCa.

Keywords: Acidic tumour microenvironment, prostate cancer, carbonic anhydrase IX, plasmatic exosomes, biomarker

1. Introduction

Extracellular acidity is a common phenotype of malignant tumours due to the “Warburg effect”. As a consequence, the anaerobic metabolism of glucose, which is triggered by hypoxia, leads to a massive accumulation of lactic acid and H+ within the cytoplasm and in the extracellular microenvironment1–6. Moreover, the extracellular acidity induces a selective pressure leading to the clonal selection of cancer cells that can survive in such a hostile condition7. Cancer cells survive and proliferate thanks to a series of innate mechanism conceivably common to all malignant tumours8–10. Among these, the proton pumps play a crucial role, reducing intracellular pH and acidifying the extracellular environment9,11,12. Therefore, tumour cells up-regulate proton exchangers and transporters throwing out excess protons through Vacuolar ATPase (V-ATPase), Na+/H + exchanger (NHE), monocarboxylate transporters (MCTs), cotransporter sodium bicarbonate (NBC), and carbonic anhydrase 9 (CA IX)2,11–13. Chemoresistance of cancers and the increase in exosome release are two well-known effects of the extracellular acidification14–18. Exosomes are extracellular nanovesicles of 40–180 nm secreted by all cells and capable of modulating physiological or pathological processes, including tumour progression, through transmitting into target cells their cargo (lipids, proteins, DNA, mRNA or microRNA)18–24. Exosomes are involved in a broad panel of cellular phenomena, including intercellular communication, elimination of toxic substances and drug delivery14,18,25,26. The acid release of the exosomes is key in tumour growth, tumour progression and metastasis18,24,27. High plasmatic levels of extracellular vesicles are related with the tumour mass28,29. It has been demonstrated that, independently from the tumour histotype, the tumour cell lines cultured at pH 6.5 released significantly higher levels of exosomes as compared to the same cells cultured at physiological pH (7.4)16,17. Recently, it has been shown that the microenvironmental low pH was consistent with a change in exosome cargo as well as with some tumour biomarkers such as Prostate Specific Antigen (PSA) and carbonic anhydrase (CA) IX16,30. CA IX is a zinc metalloenzyme belonging to a broader group of 15 isoforms involved in the catalysis of carbon dioxide hydration to bicarbonate and proton. Among these isoforms, CA IX has high clinical relevance in cancer therapy since it is implicated in tumorigenesis13,31,32 and considered a marker of tumour hypoxia33–36. CA IX is overexpressed in a large number of solid tumours, whereas its expression in normal tissues is quite limited, suggesting its role as valuable tumour biomarker. Furthermore, CA IX has been validated as a target of new therapies against hypoxic tumours with one sulphonamide inhibitor (SLC-0111) in Phase Ib/II clinical trials13,30,37–39(p20),40–42. Indeed CA IX is the most widely expressed gene in response to hypoxia, playing a pivotal role in tumour pH regulation13,30,37,41; thus conferring to cancer cells a survival advantage in hypoxic and acidic microenvironments43. Thus, it is clear that the acidic microenvironment induces the up-regulation of the CA IX expression and activity in both tumour cells30,44 and tumour released exosomes30. However, the possibility that CA IX expression and activity in cancer cell-derived exosomes could represent a new valuable tumour marker has not yet been tested in clinical samples.

In the present study, the expression and the activity of CA IX were detected in the plasmatic exosomes obtained from patients affected and non-affected by prostate carcinoma (PCa). Moreover, CA IX behaviour was correlated to the intraluminal pH of plasmatic exosomes in both patients and controls. Our results indicate that exosomal CA IX showed a higher expression and activity when compared to the controls, which were consistent with a lower intraluminal pH of the plasmatic exosomes of PCa. These data suggest that exosomal CA IX might be an interesting biomarker of cancer progression.

2. Materials and methods

2.1. Human plasma samples

Human plasma samples were collected from EDTA-treated whole blood, 5 ml into BD Vacutainer® K3-EDTA-coated collection tubes (Beckton Dickinson, USA), from prostate cancer (PCa) patients (n = 8) and healthy donors used as controls (CTR) (n = 8) attending to department of Urological Sciences, Policlinico Umberto I, Sapienza University of Rome, Italy. The study was approved by the ethics committee of IstitutoSuperiore di Sanità (ISS, Rome, Italy) on 18/04/2017 (Rif. Prot. PRE-275/17). The study was conducted in accordance with the current International Conference on Harmonisation guidelines for Good Clinical Practice and the principles of the Declaration of Helsinki. All the participants provided written informed consent.

The study population included the prostate cancer group (PCa) and the healthy donors group (CTR). The PCa group consisted of 8 male individuals consecutively referred to department of Urological Sciences, aged from 45 to 75 years, with a histologically confirmed diagnosis of prostate adenocarcinoma (prostate biopsy). None of cases were submitted to androgen deprivation therapies or other therapies that can influence PSA determination. All cases were stratified in risk classes (EAU classification) on the basis of total PSA levels (>4.5 ng/ml), Gleason score and clinical stage.

The control group (CTR) consisted of 8 male individuals consecutively referred to Urological Sciences Department with the following inclusion criteria: age from 18 to 39 years; no clinical evidence of BPH or PCa (digital rectal examination (DRE) and ultrasonography US); prostate volume less than 30 cc; no familiarity for PCa; no therapies that can influence PSA determination.

2.2. Preparation of exosomes from plasma of patients and healthy donors

To obtain exosomes from plasma samples, EDTA-treated blood from 8 patients with prostate cancer (PCa) and 8 healthy donors (CTR) was centrifuged at 400 g for 20 min. Plasma was then collected and stored at −80 °C until they will be analysed for the expression of CA IX. Upon thawing, 1 ml of plasma samples was subjected to the same centrifugal procedure as previously described45,46 in order to pellet exosomes. Plasma samples were centrifuged for 1 h 30 min at 110 000 g using a Fiberlite™ F50L-24 × 1.5 Fixed-Angle Rotor, K-Factor: 33 (ThermoFisher Scientific, USA) in Sorvall WX Ultracentrifuge Series (ThermoFisher Scientific, USA).

2.3. Nanoparticle tracking analysis

Nanoparticle tracking analysis (NTA) from Malvern (NanoSight NS300, Malvern Instruments, Malvern, UK) was used for size distribution and concentration measurements of exosomes samples in liquid suspension from the properties of both light scattering and Brownian motion. The NanoSight NS300 with a 405-nm laser instrument (Malvern Instruments, Malvern, UK) was used to detect nanovesicles. Five videos of typically 60-s duration were taken. Data were analysed using the NTA 3.0 software (Malvern Instruments) which was optimised to first identify and then track each particle on a frame-by-frame basis. The Brownian motion of each particle was tracked using the Stokes–Einstein equation: D° = kT/6πηr, where D° is the diffusion coefficient, kT/6πηr = f0 is the frictional coefficient of the particle, for the special case of a spherical particle of radius r moving with uniform velocity in a continuous fluid of viscosity η, k is Boltzmann’s constant, and T is the absolute temperature.

2.4. Western blot analysis

To perform Western blot analysis, the plasmatic exosomes pellet was resuspended in 1 ml of PBS and it was further purified by using 30% sucrose in deuterium oxide (D2O, ACROS Organics, fisher scientific, USA) density gradient ultracentrifugation for 18 h at 110,000 g, in order to eliminate contaminants46,47. Density gradient ultracentrifugation was performed by using TH-641 Rotor (ThermoFisher Scientific, USA). The 12 fractions obtained were washed in PBS for 1 h at 110,000 g and then were resuspended in CHAPS buffer 1x for subsequent experimental analysis.

Lysates were prepared in CHAPS buffer (10 mM Tris-HCl [pH 7.4], MgCl2 1 mM, EGTA 1 mM, CHAPS 0.5%, glycerol 10%, β-mercaptoethanol 5 mM, PMSF 1 mM) containing protease inhibitor cocktail. Exosomes lysates were subjected to electrophoresis on SDS polyacrylamide gels and transferred to nitrocellulose membranes (ProtranWhatman, Dassel, Germany). After blocking in 5% dry milk in PBS 1X, membranes were hybridised with primary antibodies: M7548, anti-CD81 (B-11, Santa Cruz Biotechnology, USA), anti-Alix (3A9, ThermoFisher Scientific, Waltham, MA, USA) mouse monoclonal antibodies. After incubation with appropriate peroxidase-conjugated anti-IgG (AmershamBiosciences, Milan, Italy), membranes were revealed using the ECL Chemiluminescent Substrate, (ThermoFisher Scientific, USA).

2.5. ELISA for CA IX

96 well-plates (Nunc, Milan, Italy) were coated with 4 µg/ml rabbit polyclonal anti-CD81 antibody (clone PA5-79003, Thermo Fisher Scientific, USA) in 100 µl/well of PBS and incubated overnight at 4 °C. After 3 washes with PBS, 100 µl/well of blocking solution (PBS containing 0.5% BSA) were added at room temperature for 1 h. Following 3 washes in PBS, exosomes purified from 1 ml of plasma were suspended in a final volume of 50 µl and incubated overnight at 37 °C. After 3 washes with PBS, M75 mouse monoclonal antibody48 was added to each well and incubated for 1 h at 37 °C. After 3 washes with PBS, anti-mouse HRP-conjugated was incubated in each well for 1 h at RT. After the final 3 washes with PBS, the reaction was developed with Blue POD for 15 min (Roche Applied Science, Milan), and blocked with 4 N H2SO4 stop solution. Optical densities were recorded at 450 nm.

2.6. Enzyme activity of CA IX

Exosomes were obtained from plasma of 8 prostate cancer patients (PCa) and 8 healthy donors (CTR). Exosome extracts were prepared at 4 °C using the lysis buffer (CHAPS buffer 1x) containing 1% Triton X-100, 10mMTris-HCl (pH 7.4), MgCl2 1 mM, EGTA 1 mM, CHAPS 0.5%, glycerol 10%, β-mercaptoethanol 5 mM, and supplemented with a cocktail of protease inhibitors. Aliquots of exosomes extracts containing 1 µg of total protein were used to determining the hydratase activity. The enzymatic assay was performed at 0 °C using CO2 as substrate following the pH variation due to the catalysed conversion of CO2 to bicarbonate. Bromothymol blue was used as the indicator of pH variation. The production of hydrogen ions during the CO2 hydration reaction lowers the pH of the solution until the colour transition point of the dye is reached. The time required for the colour change is inversely related to the quantity and activity of CAs present in the sample. Wilbur–Anderson units were calculated according to the following definition: One Wilbur–Anderson unit (WAU) of activity is defined as (T0 − T)/T, where T0 (uncatalyzed reaction) and T (catalysed reaction) are recorded as the time (in seconds) required for the pH to drop from 8.3 to the transition point of the dye (pH 6.8) in a control buffer and in the presence of enzyme, respectively. Enzyme activity was expressed as CA activity/mg of total protein. Protein concentration was determined using the Bio-Rad protein assay.

2.7. Flow cytometry analysis of exosomesfor evaluation of exosomal pH

Exosomal pH was evaluated by Nanoscale Flow Cytometry using the pH-sensitive fluorescent probe BCECF AM (2',7'-Bis-(2-Carboxyethyl)-5-(and-6)-Carboxyfluorescein, Acetoxymethyl Ester) (B-1170, Molecular Probes, Invitrogen, ThermoFisher Scientific, USA). Exosomes purified from 1 ml of 8 PCa and 8 CTR plasma samples were diluted in PBS in a final volume of 40 µl. Anti-human CD81 allophycocyanin (APC) conjugated (Beckman Coulter; Brea, CA, USA) and BCECF AM (B-1170, Molecular Probes, Invitrogen, ThermoFisher Scientific, USA) were added to the exosome preparation at optimal pre-titered concentrations and left for 20 min at RT. Anti IgG2a APC (Beckman Coulter; Brea, CA, USA) was used for isotype control.500 µl of PBS were added to samples before the acquisition on the CytoFLEX flow cytometer (Beckman Coulter, Brea, CA, USA). The cytometer was calibrated using a mixture of non-fluorescent silica beads and fluorescent (green) latex beads with sizes ranging from 110 nm to 1300 nm. This calibration step enables the determination of the sensitivity and resolution of the flow cytometer (fluorescent latex beads) and the size of extracellular vesicles (silica beads). CD81 was labelled in allophycocyanin (APC) that absorbs and emits red light (650 and 660 nm max, respectively). BCECF, which emits fluorescence once it enters into the acidic milieu, absorbs and emits green light (488 and 525/640 nm). All samples were acquired at low flow rate for the same amount of time in order to obtain an estimate of absolute counts of exosomes comparable between various samples. The analysis of the data was performed with FlowJo software (FlowJo, LLC; Ashland, Oregon, USA)16.

2.8. Cell line

Human prostate carcinoma cell line (LNCaP) is derived from a metastatic site (left supraclavicular lymph node) of a 50-year-old Caucasian male (blood type B+) with confirmed diagnosis of metastatic prostate carcinoma (IstitutodeiTumori di Milano). Tumour cells were negative for Mycoplasma contamination as routinely tested by PCR (Venor®GeM, Minerva Biolabs, Germany). The cells were maintained in RPMI 1640 without sodium bicarbonate culture medium at pH 6.5 supplemented with antibiotics and 10% foetal calf serum (FCS) (Invitrogen, Milan, Italy), at 37 °C in humidified 5% CO2. The acid cell culture medium (pH 6.5) was obtained by the addition of 1 M HCl solution. The pH was measured with a pH 123 Microprocessor pH Metre (Hanna Instruments, Milan, Italy). LNCaP cells were slowly adjusted to pH 6.5 for a sufficient time starting from unbuffered conditions, allowing tumour cells to acidify the microenvironment themselves. After five days in unbuffered medium, measured pH of the culture was 6.5. Thus, we progressively conditioned the pH of the cultures starting from 7.4 until pH 6.5 in a time ranging from three to four weeks, allowing the cells to not be exposed to short-term pH stress17.

2.9. Laser scanning confocal microscopy (LSCM)

About 1 x 105 cells/well of LNCaP cells cultured at pH 6.5 were seeded on coverslips in 24-well plate. After 24 h, cells were stained with BCECF AM (Molecular Probes, ThermoFisher Scientific, USA) (10 µM) for 30 min at 37 °C. After being fixed in 4% paraformaledehyde, cells were blocked for 1 h at RT in PBS with 1% BSA and labelled with CD9-PE mouse monoclonal antibody (clone LM-L13 (RUO), BD Biosciences, USA) for 1 h at RT; then cells were incubated with M75 mouse monoclonal antibody48 for 1 h at RT, following from incubation with anti-mouse Alexa Fluor® 647 secondary antibody (Abcam, UK). After washes in PBS, coverslips with DAPI + ProLong (Vector Laboratories, Burlingame, CA) were transferred on microscope slides and images were acquired with an inverted microscope (Nikon Ti-E)equipped with a confocal spectral imaging system (Nikon D Eclipse C1si) using a (Nikon) PlanApo objective 60× oil (numerical aperture 1.4). Excitation light was obtained by a Laser Dapi (408 nm) for DAPI, an Argon Ion Laser (488 nm) for BCECF, Diode Laser HeNe (561 nm) for CD9-PE, and a Red Diode Laser (638 nm) for Alexa 647. Emitted fluorescence was recorded in spectral – frame lambda mode. DAPI emission was recorded from 415 to 485 nm, BCECF emission was recorded from 495 to 550 nm, CD9-PE emission was recorded from 583 to 628 nm, and Alexa 647 from 634 to 750 nm. Images recorded have an optical thickness of 0.20 µm and have been analysed by the C1-LCSI EZ-C1 software for spectral analysis. Signals from different fluorescent probes were taken in sequential scanning mode, several fields were analysed for each labelling condition, and representative results are shown.

2.10. Statistical analysis

Results in the text are expressed as means ± standard error (SE), calculated using the GraphPad Prism software. The statistical analysis was done with an unpaired t-test (Student’s t-test).

3. Results

3.1. CA IX expression is up-regulated in exosomes isolated from plasma of prostate cancer (PCa) patients

A series of experiments aimed at evaluating the level of CA IX expression and activity in exosomes purified from PCa and control (CTR) plasma has been performed. Exosomes isolated by ultracentrifugation were characterised and quantified by Nanoparticle Tracking Analysis (NTA) and the expression of the exosomal markers Alix and CD81. PCa patients showed higher plasmatic levels of exosomes than the controls (p < .1) (Figure 1(A–C)). Moreover, exosomes from PCa patients were more homogeneous in size distributionin respect to plasmatic exosomes from CTR (Figure 1(A–C)). Thus, to eliminate contaminants, the Western Blot Analysis of plasmatic exosomes purified by differential ultracentrifugation and further using 30% sucrose density gradient ultracentrifugation was performed46,47. The resulting fractions were blotted for CA IX and exosomal markers (Alix and CD81). The results showed that CA IX expression was up-regulated in exosomal purification lysates from PCa plasma patients (Figure 2(A)) as compared to the exosomal fractions of CTR plasma (Figure 2(B)). Figure 2 also shows that the CA IX band corresponded to the typical exosome fractions as identified by the expression of Alix and CD81 in the second and third fractions of the density gradient. As shown in Figure 2(A), CA IX in PCa exosomes is evidenced by the presence of two bands (58/54 kDa). The CTR exosomes (Figure 2(B)) exclusively showed the Alix and CD81 bands.

Figure 1.

Figure 1.

Open in a new tab

Nanoparticle tracking analysis (NTA) quantification of exosomes released from plasma of PCa patients and CTR. (A) NTA distribution of CTR exosomes. (B) NTA distribution of PCa exosomes. (C) Concentration (particles/ml) of exosomes. Mean ± SE of plasma exosomes from 8 CTR and 8 PCa patients are shown. The p values was <.1 in PCa plasma respect to CTR plasma exosomes. *p < .1.

Figure 2.

Figure 2.

Open in a new tab

Western blot analysis of plasmatic exosomes from PCa patients and CTR after 30% sucrose density gradient ultracentrifugation for housekeeping markers (Alix and CD81) and CA IX expression. (A) Protein characterisation of exosomal fractions purified from plasma of PCa patients performed with anti-Alix, anti-CD81 and M75 (CA IX). (B) Protein characterisation of exosomal fractions purified from plasma of CTR performed with anti-Alix, anti-CD81 and M75 (CA IX).

3.2. CA IX positive exosomes are over-expressed in PCa plasma patients: characterisation and quantification by ELISA test

To support this set of results, we exploited an immunocapture-based ELISA assay to quantify and characterise CA IX expression levels in exosomes purified from 1 ml of either PCa or CTR plasma, by seeding the same amount of exosomes preparations (50 µl). The results showed that the CA IX positive exosomes were 25-fold higher in plasma of PCa patients (558 ± 90) than in CTR (22 ± 2), (p < .0001) (Figure 3). The plasma deprived of exosomes was entirely negative for both markers (data not shown).

Figure 3.

Figure 3.

Open in a new tab

Detection, quantification and characterisation of CAIX+/CD81+ exosomes purified from PCa and CTR plasma by ELISA test. ELISA analysis of CAIX and CD81 expression in exosomes purified from plasma of 8 PCa patients and 8 CTR (1 ml for each sample). Rabbit polyclonal anti-CD81 antibody was used for the capture of exosomes on the plate. Expression levels of exosomal CAIX were expressed as means ± ES. The p values was <.0001 in PCa plasma exosomes respect to CTR plasma exosomes. ****p < .0001.

3.3. CA enzymatic activity analysis of PCa and CTR plasma exosomes

The CA IX-activity of exosomes isolated from plasma of PCa and CTR has been analysed using the colorimetric CA assay as described in the “Materials and Methods” section. The results showed that the CA-activity/mg protein found in exosomes isolated from PCa plasma (2.9 ± 0.4) was 2.4-fold higher as compared to exosomes purified from CTR plasma (1.2 ± 0.2) (p < .0001) (Figure 4); thus supporting that the increased CA IX expression in plasmatic exosomes of PCa patients was consistent with a real enzyme activity up-regulated in PCa plasma exosomes. This result is, of course, of paramount importance since circulating exosomes may export to other tissues a function that appears to be associated with malignancy.

Figure 4.

Figure 4.

Open in a new tab

Analysis of CAIX enzymatic activity of plasma exosomes from PCa and CTR. CA IX activity is shown for plasma exosomes purified from 8 PCa patients and 8 CTR. The results were expressed as means ± SD of CA-activity/mg protein found in exosomes. The p values was <.0001 in PCa plasma exosomes respect to CTR plasma exosomes. ****p < .0001.

3.4. Exosomes from PCa plasma patients are acidic

Recently, our groups showed that the tumour acidic microenvironment markedly increases the number of exosomes, also those expressing CA IX16,17,30. However, never the acidity of the tumour microenvironment has been associated with the intraluminal acidification of the exosome released by cancer cells. Thus, in this set of experiments we studied the intraluminal pH in plasmatic exosome preparations from either PCa or CTR. Plasmatic exosomes purified from PCa and CTR samples were analysed using Nanoscale Flow Cytometry (Cytoflex) for the presence of typical exosomal CD81 marker, and the expression of the fluorescent indicator for cytosolic pH, BCECF.

Double-positive events were counted and analysed by size. The results showed that the number of double-positive exosomes smaller than 180 nm was higher in PCa patients as compared to CTR (Figure 5). Figure 5 shows the absolute average number of CD81+/BCECF + exosomes (sizes less than 180 nm) obtained from either PCa or CTR plasma. In particular, the amount of acidic exosome was 2-folds higher in PCa plasma (10 510 ± 2551) as compared to CTR plasma (6184 ± 1015) (p < .1). These results evidenced for the first time that an intraluminal acidic pH characterised the exosomes of PCa plasma patients. It is consistent with the higher expression and activity of a CA IX, a protein associated with both acidity and hypoxia. The statistical analysis was performed using the unpaired t-test with the GraphPad Prism 6 software.

Figure 5.

Figure 5.

Open in a new tab

Nanoscale flow cytometry of plasma exosomes in PCa and CTR for intraluminal pH evaluation. The cytometer was calibrated using a mixture of non-fluorescent silica beads and fluorescent (green) latex beads with sizes from 110 nm to 1300 nm. The exosome preparation derived from plasma of 8 PCa patients and 8 CTR were stained 20 min at RT with anti-CD81 antibody and BCECF AM (10 µM) and analysed using flow cytometry. The double-positive events were then analysed for their size, based on the calibration with beads. Cumulative data are shown of the absolute number of CD81+/BCECF + exosomes of size less than 180 nm recovered from the plasma samples. Data are expressed as means ± SE. The p values was <.1 in PCa plasma exosomes compared to CTR. *p < .1.

3.5. Acidic tumour microenvironment up-regulates CA-IX expression

The CA IX expression was determined and compared to the level of intracellular acidity in a human prostate cancer cell line (LNCaP) cultured at pH 6.5. Intracellular acidity was analysed by Confocal Microscopy using BCECF, the fluorescent tracer. The results showed a massive cytoplasmic distribution of BCECF (in green) (Figure 6(B)) in LNCaP cultured in acidic conditions. This is due to the intake of BCECF into the cells triggered by the low intracellular pH. The BCECF staining was consistent with the CD9 staining (an exosome marker), predominantly at the plasma membrane level, while detectable at the cytoplasm level as well (Figure 6(C)). Interestingly, we showed a similar distribution of CA IX expression (in gray). It is mainly localised at the plasma membrane, also into the cytoplasm, but associated with the nuclear membrane as well (Figure 6(D)). Figure 6(E) shows the merged distribution within the LNCaP cells of the four fluorescent dyes used to identify the nucleus (blue), BCECF (green), CD9 (red) and CA IX (gray). CD9/CA IX is co-localised within low pH cultured cancer cells. The staining partially overlaps the BCECF fluorescence suggesting that CA IX is expressed during exosome release in acidic conditions and that these exosomes are acidic as well.

Figure 6.

Figure 6.

Open in a new tab

Confocal microscopy analysis of BCECF and CA IX expression in LNCaP cell line cultured at pH 6.5. (A) Isotype control cell. (B) LNCaP cell labelled with BCECF (green signal). (C) LNCaP cell labelled with CD9 monoclonal antibody (M-L13, RUO, red signal). (D) LNCaP cell incubated with M75 and then with Alexa Fluor® 647 secondary antibody for CA IX detection (gray signal). (E) Merged image of different signals on LNCaP cells: BCECF (green signal), CD9 (red signal), CA IX (grey signal), nucleus (blue signal of DAPI).

4. Discussion

Among the phenotypes common to virtually all malignant tumours are hypoxia, acidity, and low nutrient supply1–5 and ROS hyperproduction, as recently described49. In particular, acidic extracellular microenvironment induces a selective pressure leading to selection of cancer cells armed to survive in extreme microenvironmental conditions7. Between these adaptive advantages, cancer cells implement a series of strategies, making them very similar to unicellular organisms8,10. However, to prevent intracellular H+ accumulation cancer cells upregulates proton exchangers that extrude protons in excess contributing to acidify extracellular tumour microenvironment9,11,12. Among these proton exchangers, a primary role is played by CA IX, an enzyme overexpressed in many types of cancers, including prostate cancer, with the potential to represent both a promising tumour biomarker and a specific target for future cancer therapies13,30–33,37–41,44. Under the pressure of the acidic microenvironment, CA IX expression and activity are upregulated in both tumour cells30,44 and the exosomes released extracellularly30. In order to support a real clinical impact of the previous information, we performed a pilot clinical study in which exosomes purified from plasma of prostate cancer patients have been compared to plasmatic exosomes from healthy controls. We analysed the expression and function of CA IX in plasmatic samples, hypothesising that this was related to the decreased intraluminal pH. The results of this study show for the first time that (i) exosomes purified from plasma of patients with prostate cancer express significantly higher levels of CA IX, through different methodological approaches, such as western blot analysis, in both the whole exosome lysates and sucrose gradients, and immunocapture based ELISA; (ii) the increased CA IX exosome expression corresponded to a real function inasmuch as exosomes purified from plasma of patients with prostate cancer showed a significantly higher CA-activity; (iii) exosomes purified from plasma of patients with prostate cancer are acidic, as shown by Nanoscale Flow Cytometry and (IV) CA-IX, exosome markers and intraluminal low pH co-localize in exosome released by prostate cancer cells in acidic conditions, as shown by confocal microscopy. A significant difference in CA IX expression was that circulating exosomes of cancer patients expressed a double band at 58/54 kDa, suggesting the occurrence of post-transcriptional changes of CA IX expression induced by the tumour condition.

All in all our study shows for the first time a correlation between CA IX expression and intraluminal acidity in plasmatic exosomes of cancer patients. Confocal microscopy showed that a high intracellular acidity characterises prostate cancer cells stably cultured at pH 6.5, as demonstrated by the massive intake of BCECF in these cells; this was consistent with a clear co-localization of the exosomal marker CD9 and CA IX, mainly at the plasma membrane, while co-expressed at the cytoplasm and the nuclear membrane levels, as well. The concentration of CA IX/CD9/acidic particles at the plasma membrane suggests an increased activity of the endosomal compartment, in turn, leading to exosome formation and extracellular release. These results indicate that tumour acidic microenvironment is the crucial factor in affecting the CA IX expression and activity in prostate cancer cells and cancer-released exosomes. It appears conceivable that the microenvironmental tumour acidity may increase exosomes release, together with the upregulation of CA IX expression and activity in PCa. Therefore, the increase of plasmatic levels of CA IX/acidic exosomes in prostate cancer patients may be the result of the spill-over of these exosomes from the tumour to the bloodstream. Indeed CA IX is a transmembrane protein whose catalytic domain exhibits the fundamental biochemical and biophysical properties that allow stability and activity at low pH34,50. Conversely, CA IX expression and activity is down-regulated in healthy donors plasma exosomes since under normal conditions, the cells don’t need a high expression and activity of the proton exchangers because they use oxidative metabolism. The key role of the acidic tumour microenvironment in increasing the release of exosome by cancer cells support our previous studies16,17,27,30.

Our study supports a new idea for providing reliable tumour markers suitable for clinical use. Here, we have shown that plasmatic exosomes from cancer patients overexpress CA IX and together with exerting a CA IX-related activity. This is probably the first translational evidence in this sense; that is the expression of a protein plus the activity related to the expressed protein, may represent a new and non-invasive diagnostic tool with a potentially high clinical impact in early diagnosis and monitoring of prostatic cancer, but conceivably all malignant tumours as well.

Acknowledgements

The authors would like to thank Dr Silvia Pastoreková (Biomedical Research Centre, Slovak Academy of Sciences) for kindly providing us with the antibody M75 used in this study.

Disclosure statement

No potential conflict of interest was reported by the authors.

References

  • 1.Warburg O. On the origin of cancer cells. Science 1956;123:309–14. [DOI] [PubMed] [Google Scholar]
  • 2.Fais S, Venturi G, Gatenby B.. Microenvironmental acidosis in carcinogenesis and metastases: new strategies in prevention and therapy. Cancer Metastas Rev 2014;33:1095–108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Gatenby RA, Gillies RJ.. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004;4:891–9. [DOI] [PubMed] [Google Scholar]
  • 4.Vander Heiden MG, Cantley LC, Thompson CB.. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029–33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Cairns RA, Harris IS, Mak TW.. Regulation of cancer cell metabolism. Nat Rev Cancer 2011;11:85–95. [DOI] [PubMed] [Google Scholar]
  • 6.Neri D, Supuran CT.. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 2011;10:767–77. [DOI] [PubMed] [Google Scholar]
  • 7.Gillies RJ, Brown JS, Anderson ARA, Gatenby RA.. Eco-evolutionary causes and consequences of temporal changes in intratumoural blood flow. Nat Rev Cancer 2018;18:576–85. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Fais S, Fauvarque M-O.. TM9 and cannibalism: how to learn more about cancer by studying amoebae and invertebrates. Trends Mol Med 2012;18:4–5. [DOI] [PubMed] [Google Scholar]
  • 9.Fais S. A non-mainstream approach against cancer. J Enzyme Inhib Med Chem 2016;31:882–9. [DOI] [PubMed] [Google Scholar]
  • 10.Fais S, Overholtzer M.. Cell-in-cell phenomena in cancer. Nat Rev Cancer 2018;18:758–66. [DOI] [PubMed] [Google Scholar]
  • 11.Spugnini EP, Sonveaux P, Stock C, et al. . Proton channels and exchangers in cancer. Biochim Biophys Acta BBA – Biomembr 2015;1848:2715–26. [DOI] [PubMed] [Google Scholar]
  • 12.Iessi E, Logozzi M, Mizzoni D, et al. . Rethinking the combination of proton exchanger inhibitors in cancer therapy. Metabolites 2017;8:2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Supuran CT, Winum J-Y.. Carbonic anhydrase IX inhibitors in cancer therapy: an update. Future Med Chem 2015;7:1407–14. [DOI] [PubMed] [Google Scholar]
  • 14.Federici C, Petrucci F, Caimi S, et al. . Exosome release and low pH belong to a framework of resistance of human melanoma cells to cisplatin. PLoS One 2014;9:e88193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Taylor S, Spugnini EP, Assaraf YG, et al. . Microenvironment acidity as a major determinant of tumor chemoresistance: proton pump inhibitors (PPIs) as a novel therapeutic approach. Drug Resist Updat 2015;23:69–78. [DOI] [PubMed] [Google Scholar]
  • 16.Logozzi M, Angelini DF, Iessi E, et al. . Increased PSA expression on prostate cancer exosomes in in vitro condition and in cancer patients. Cancer Lett 2017;403:318–29. [DOI] [PubMed] [Google Scholar]
  • 17.Logozzi M, Mizzoni D, Angelini D, et al. . Microenvironmental pH and exosome levels interplay in human cancer cell lines of different histotypes. Cancers 2018;10:370. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Logozzi M, Spugnini E, Mizzoni D, et al. . Extracellular acidity and increased exosome release as key phenotypes of malignant tumors. Cancer Metastasis Rev 2019;38:93–101. [DOI] [PubMed] [Google Scholar]
  • 19.Valadi H, Ekström K, Bossios A, et al. . Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007;9:654–9. [DOI] [PubMed] [Google Scholar]
  • 20.Camussi G, Deregibus M-C, Bruno S, et al. . Exosome/microvesicle-mediated epigenetic reprogramming of cells. Am J Cancer Res 2011;1:98–110. [PMC free article] [PubMed] [Google Scholar]
  • 21.Nolte’tHoen ENM, Buermans HPJ, Waasdorp M, et al. . Deep sequencing of RNA from immune cell-derived vesicles uncovers the selective incorporation of small non-coding RNA biotypes with potential regulatory functions. Nucleic Acids Res 2012;40:9272–85. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Canitano A, Venturi G, Borghi M, et al. . Exosomes released in vitro from Epstein–Barr virus (EBV)-infected cells contain EBV-encoded latent phase mRNAs. Cancer Lett 2013;337:193–9. [DOI] [PubMed] [Google Scholar]
  • 23.Zhao H, Achreja A, Iessi E, et al. . The key role of extracellular vesicles in the metastatic process. Biochim Biophys Acta BBA - Rev Cancer 2018;1869:64–77. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Spugnini E, Logozzi M, Di Raimo R, et al. . A role of tumor-released exosomes in paracrine dissemination and metastasis. Int J Mol Sci 2018;19:3968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Iessi E, Logozzi M, Lugini L, et al. . Acridine orange/exosomes increase the delivery and the effectiveness of acridine orange in human melanoma cells: a new prototype for theranostics of tumors. J Enzyme Inhib Med Chem 2017;32:648–57. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Kusuzaki K, Matsubara T, Murata H, et al. . Natural extracellular nanovesicles and photodynamic molecules: is there a future for drug delivery? J Enzyme Inhib Med Chem 2017;32:908–16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Parolini I, Federici C, Raggi C, et al. . Microenvironmental pH is a key factor for exosome traffic in tumor cells. J Biol Chem 2009;284:34211–22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Logozzi M, De Milito A, Lugini L, et al. . High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS One 2009;4:e5219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Rodríguez Zorrilla S, Pérez-Sayans M, Fais S, et al. . A pilot clinical study on the prognostic relevance of plasmatic exosomes levels in oral squamous cell carcinoma patients. Cancers 2019;11:429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Logozzi M, Capasso C, Di Raimo R, et al. . Prostate cancer cells and exosomes in acidic condition show increased carbonic anhydrase IX expression and activity. J Enzyme Inhib Med Chem 2019;34:272–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Supuran CT. Carbonic anhydrase inhibition and the management of hypoxic tumors. Metabolites 2017;7:48. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Li Y, Dong M, Sheng W, Huang L.. Roles of carbonic anhydrase IX in development of pancreatic cancer. Pathol Oncol Res 2016;22:277–86. [DOI] [PubMed] [Google Scholar]
  • 33.Ambrosio MR, Di Serio C, Danza G, et al. . Carbonic anhydrase IX is a marker of hypoxia and correlates with higher Gleason scores and ISUP grading in prostate cancer. Diagn Pathol 2016;11:45. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Mahon BP, Bhatt A, Socorro L, et al. . The structure of carbonic anhydrase IX is adapted for low-pH catalysis. Biochemistry 2016;55:4642–53. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Rosenberg V, Pastorekova S, Zatovicova M, et al. . High serum carbonic anhydrase IX predicts shorter survival in head and neck cancer. Bratisl Lek Listy 2016;117:201–4. [DOI] [PubMed] [Google Scholar]
  • 36.Horie K, Kawakami K, Fujita Y, et al. . Exosomes expressing carbonic anhydrase 9 promote angiogenesis. Biochem Biophys Res Commun 2017;492:356–61. [DOI] [PubMed] [Google Scholar]
  • 37.Supuran CT, Alterio V, Di Fiore A, et al. . Inhibition of carbonic anhydrase IX targets primary tumors, metastases, and cancer stem cells: three for the price of one. Med Res Rev 2018;38:1799–836. [DOI] [PubMed] [Google Scholar]
  • 38.Lucarini L, Magnelli L, Schiavone N, et al. . Plasmatic carbonic anhydrase IX as a diagnostic marker for clear cell renal cell carcinoma. J Enzyme Inhib Med Chem 2018;33:234–40. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Cetin B, Gonul II, Gumusay O, et al. . Carbonic anhydrase IX is a prognostic biomarker in glioblastoma multiforme: carbonic anhydrase IX and glioblastoma multiforme. Neuropathology 2018;38:457–62. [DOI] [PubMed] [Google Scholar]
  • 40.Lin C, Wong BCK, Chen H, et al. . Pulmonary delivery of triptolide-loaded liposomes decorated with anti-carbonic anhydrase IX antibody for lung cancer therapy. Sci Rep 2017;7:2019–23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Riemann A, Güttler A, Haupt V, et al. . Inhibition of carbonic anhydrase IX by ureidosulfonamide inhibitor U104 reduces prostate cancer cell growth, but does not modulate daunorubicin or cisplatin cytotoxicity. Oncol Res Featur Preclin Clin Cancer Ther 2018;26:191–200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Hedlund EE, McDonald PC, Nemirovsky O, et al. . Harnessing induced essentiality: targeting carbonic anhydrase IX and angiogenesis reduces lung metastasis of triple negative breast cancer xenografts. Cancers 2019;11:1002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Benej M, Pastorekova S, Pastorek J, Carbonic anhydrase IX: regulation and role in cancer. In: Frost SC, McKenna R, editors. Carbonic anhydrase: mechanism, regulation, links to disease, and industrial applications. Vol. 75. Dordrecht: Springer Netherlands; 2014. p. 199–219. [DOI] [PubMed] [Google Scholar]
  • 44.Andreucci E, Peppicelli S, Carta F, et al. . Carbonic anhydrase IX inhibition affects viability of cancer cells adapted to extracellular acidosis. J Mol Med 2017;95:1341–53. [DOI] [PubMed] [Google Scholar]
  • 45.Caby M-P, Lankar D, Vincendeau-Scherrer C, et al. . Exosomal-like vesicles are present in human blood plasma. Int Immunol 2005;17:879–87. [DOI] [PubMed] [Google Scholar]
  • 46.Théry C, Witwer KW, Aikawa E, et al. . Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles 2018;7:1535750. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Théry C, Amigorena S, Raposo G, Clayton A.. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol 2006;30:3.22.1–3.22.29. [DOI] [PubMed] [Google Scholar]
  • 48.Pastoreková S, Závadová Z, Košťál M, et al. . A novel quasi-viral agent, MaTu, is a two-component system. Virology 1992;187:620–6. [DOI] [PubMed] [Google Scholar]
  • 49.Logozzi M, Mizzoni D, Di Raimo R, et al. . Oral administration of fermented papaya (FPP®) controls the growth of a murine melanoma through the in vivo induction of a natural antioxidant response. Cancers 2019;11:118. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Innocenti A, Pastorekova S, Pastorek J, et al. . The proteoglycan region of the tumor-associated carbonic anhydrase isoform IX acts as anintrinsic buffer optimizing CO2 hydration at acidic pH values characteristic of solid tumors. Bioorg Med Chem Lett 2009;19:5825–8. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Enzyme Inhibition and Medicinal Chemistry are provided here courtesy of Taylor & Francis

RESOURCES